News

December 22nd, 2017 14:12 R
Immunovia expands multicenter clinical study for early detection of pancreatic cancer through collaboration with the renowned University of Pittsburgh

The collaboration with leading pancreas cancer centers in USA is a cornerstone of Immunovias reimbursement strategy and market introduction. The present expansion of PanFAM-1, the largest ever prospective multicenter study for early detection of pancreas cancer is another important step towards these goals.  The study is designed to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer


Release

December 20th, 2017 14:12 R
Sahlgrenska University Hospital first Swedish site in the largest ever prospective clinical study for early detection of pancreatic cancer

Designed to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer 


Release

December 18th, 2017 08:12 R
Immunovia initiates the world’s largest study of new onset diabetic patients in a prospective pancreas cancer study supported by SWElife

Sample collection providing access of up to 6 000 new onset diabetic patients is based on a collaboration including Sweden´s two major universities Lund and Uppsala, Lund University Diabetic Center, as well as Skåne and Uppsala healthcare regions.


Immunovia SWElife 20171218

November 10th, 2017 08:11 R
Immunovia Interim report, January-September 2017

“The important prospective studies for the pancreas test within the diabetes group (“PANDIA-1”) and the early symptoms group (“PANSYM-1”) have in discussions with clinical partners made progress for both PANDIA-1 and PANSYM-1. At the end of October, collection of blood samples began from patients with early symptoms at University College London Hospital. This was a very significant milestone for PANSYM-1. The retrospective, diabetes risk-group study based on the biobank from Region Skåne is also now under way.”


Release

November 7th, 2017 14:11 R
Immunovia AB (Publ) nomination committee appointed for AGM 2018

According to the instruction that was adopted at the Immunovia AB (Publ) AGM April 25 2017, the nomination committee should consist of three members.


Release

November 2nd, 2017 08:11 R
University College London Hospital starts the collection of blood samples to evaluate IMMray™ PanCan-d in symptomatic patients

University College London Hospital will assess Immunovia’s IMMray™ PanCan-d in 360 patients with symptoms suggestive of early pancreatic cancer


Release

October 31st, 2017 17:10 R
Increase in share capital and number of shares in Immunovia

The share capital and number of shares in Immunovia AB (publ) has changed due to share warrants being exercised in the company.

·          The share capital has increased from SEK 840,902.95 to SEK 865,902.95.
·          The number of shares has increased by 514,000 to 17,318,059 shares.
·          The dilution amounts to 3.1%.


Release

October 30th, 2017 16:10 R
Immunovia receives SEK4.9 Million grant from Swelife Accelerator Innovation Program

The grant supports completion of the development studies of IMMray™ PanCan-d, the first blood-based test for early stage pancreatic cancer to enable increased possibility of successful surgical intervention.


Release

October 23rd, 2017 10:10 R
Immunovia signs major autoimmune biomarker discovery collaboration with Linköping University

Aim to develop next generation of autoimmune diseases diagnostics based on IMMray™ antibody array platform.


Release

September 26th, 2017 18:09 R
Management and employees of Immunovia subscribe for new shares by exercising warrants


Release

September 7th, 2017 15:09 R
Immunovia announces collaboration with Lund University Diabetes Centre for the early detection of pancreatic cancer in diabetes risk group

LUND, Sweden ― Immunovia AB is delighted to announce a collaboration with the researchers at Lund University Diabetes Centre (LUDC) to validate the company´s biomarker signature in high risk group of newly-onset type 2 diabetics (NoD) patients over the age of 50. The risk of these patients to develop pancreatic cancer is over 8 times greater than that of the general population. 


PR Immunovia LUDC retro diabetes ENG

August 23rd, 2017 08:08 R
Immunovia Interim report, January-June 2017

“During Q2 we announced that we are establishing our American office in Boston. The head office for the US includes our own reference laboratory that complements our earlier collaboration with Knight Diagnostic Laboratories and gives us delivery capacity in both the east and west of the United States.”

“Another highlight for Immunovia during the quarter was the excellent results from the study of differentiation of Rheumatoid Arthritis (RA), Sjögren’s Syndrome and Systemic Vasculitis. These results complement the ones from the earlier differential study that we presented for SLE in Q1. They further confirm that our IMMrayTMplatform is generally applicable for many unsolved clinical problems within both cancer and autoimmunity while specifically strengthening our possibilities in the autoimmunity field.”

“During the quarter we announced that, together with Knight Cancer Institute at OHSU, we received a research grant from PanCAN, a patient advocacy group, to support a retroactive analysis of American patients who developed pancreatic cancer after being diagnosed with diabetes.”


Release

July 17th, 2017 08:07 R
Leading expert on pancreatic cancer, Professor Stephen Pereira at University College London, joins Immunovia’s Scientific Advisory Board

LUND, Sweden ― Immunovia announced today that Professor Stephen Pereira, one of the globally leading experts in the diagnosis of early symptoms of pancreatic cancer and a multidisciplinary diagnostic center champion has been appointed to the company’s Scientific Advisory Board. Currently, Pereira is Professor of Hepatology & Gastroenterology at UCL, University College London, and an honorary consultant in pancreaticobiliary medicine at UCL Hospitals and The Royal Free Hospital.  


Release

June 30th, 2017 08:06 R
Immunovia together with Oregon Health and Science University awarded one of the Pancreatic Cancer Action Network 2017 Research Grants

LUND, Sweden ― On the 28th of June, it was announced that Pancreatic Cancer Action Network (PanCAN), the largest patient advocacy group in USA, in partnership with generous donors, awarded Prof. Brett Sheppard and Prof. Rosalie Sears from Oregon Health and Science University one of the Research grants for 2017 of a value of $ 250.000.


Release

June 28th, 2017 08:06 R
Immunovia establishes US headquarters, including CLIA reference laboratory, in Boston

LUND, Sweden ― Immunovia today announces that Boston, Massachusetts USA, has been chosen as the location for the headquarters of Immunovia Inc, a wholly owned subsidiary of Immunovia AB, and that the facility agreements have been finalized.  This new Immunovia site is designed to accommodate a CLIA accredited reference laboratory for the Eastern USA as well as facilitating commercialization, covering marketing, sales and customer support.


Release

June 21st, 2017 08:06 R
Immunovia’s IMMray™ presents biomarkers that differentiates Rheumatoid Arthritis from other autoimmune diseases with 89% accuracy

LUND, Sweden - Immunovia today announced that they have completed the analysis of the three other autoimmune diseases included in the previously reported large, retrospective autoimmune disease study, performed in collaboration with Department of Immuntechnology, Lund University. The study included 315 blood samples and covered main autoimmune indications such as, Systemic Lupus Erythematosus Rheumatoid Arthritis (RA), Sjögren’s Syndrome, Systemic Vasculitis and healthy controls. For SLE, two sets of differential diagnosis data were previously reported March 7 2017.


Release

June 16th, 2017 08:06 R
Immunovia AB announces timetable for listing on Nasdaq Stockholm's main market

LUND, Sweden - The Board of Directors of Immunovia AB today announces timetable for the application for listing of the company's shares on Nasdaq Stockholm's main market. Immunova's shares are currently traded on Nasdaq First North under the ticker IMMNOV.


Release

June 13th, 2017 15:06 R
Immunovia´s biomarker signature for the diagnosis of pancreatic cancer now patented in Japan

LUND, Sweden ― Immunovia is delighted to announce the grant by the Japanese Patent Office of a patent for its biomarker signature for the diagnosis of pancreatic cancer.  Japanese Patent No. JP 6115801, is the first patent awarded to Immunovia in Japan covering its proprietary IMMray™ PanCan-d test. 


Release

April 25th, 2017 17:04 R
Immunovia Stämmokommuniké

Årsstämma i Immunovia AB (publ), 556730-4299, har hållits den 25 april 2017 i Gamla Gästmatsalen på Medicon Village, Scheelevägen 2, Lund. Nedan följer en sammanfattning av de beslut som fattades.


Release

April 20th, 2017 08:04 R
Immunovia Interim report, January-March 2017


Release

March 24th, 2017 08:03 R
IMMUNOVIA AB KALLAR TILL ÅRSSTÄMMA OCH PUBLICERAR ÅRSREDOVISNING FÖR RÄKENSKAPSÅRET 2016


Release

March 7th, 2017 08:03 R
Final data from major Swedish study confirms that IMMray™ biomarker microarray differentiates SLE from other autoimmune diseases with 96% accuracy

LUND, Sweden: Immunovia today announced that the large retrospective autoimmune disease study, performed in collaboration with Lund University’s IDEA Centre has been finalized. The study, first reported in January 2017, included 315 blood samples and was specifically designed to assess the effectiveness of IMMray™ blood-based biomarker signatures in differentiating SLE from three other main autoimmune diseases: rheumatoid arthritis, Sjögren disease and vasculitis. There is a clear clinical need for such a test since more than 50% of SLE patients are being initially misdiagnosed, mainly due to ambiguous laboratory test results.


Release

February 22nd, 2017 08:02 R
Immunovia tillkännager genomförd blocktransaktion i bolagets aktier


Release

February 15th, 2017 08:02 R
Immunovia Financial Statement 2016


Release

February 14th, 2017 10:02 R
Immunovia inbjuder till telefonkonferens den 15 februari 2017

Immunovia inbjuder till telefonkonferens i samband med rapportering av helårsresultatet för 2016. Telefonkonferensen äger rum kl. 16.00 den 15 februari och resultatet beräknas
publiceras kl. 08.00 samma dag.


Release

February 13th, 2017 11:02 R
Immunovia presenterar vid Vator Securities Unicorn Summit

Vator Securities Unicorn Summit är en kapitalmarknadsdag med några av de mest intressanta svenska Life Science-bolagen. Eventet anordnas den 7 mars 2017 på IVA i Stockholm, med start klockan 11.30.


Release

January 16th, 2017 11:01 R
University of Michigan Pancreatic Cancer Center new partner in Immunovia’s global PANFAM-1 prospective validation study

LUND, Sweden, and Ann Arbor, USA ― Immunovia AB is pleased to announce that the University of Michigan Pancreatic Cancer Center has become the most recent member of the global network of prominent sites participating in the PANFAM-I prospective clinical study for the early diagnosis of pancreatic cancer in high risk individuals.


Release

January 12th, 2017 18:01 R
Immunovia announces first data exceeding 90% accuracy in distinguishing systemic lupus erythematosus (SLE) from other autoimmune diseases in new study

LUND, Sweden ― Immunovia today announced that the principal aim of a large retrospective study, performed in collaboration with Lund University’s IDEA Centre, has been achieved. The data confirms that IMMray™ biomarker signatures can distinguish Systemic Lupus Erythematosus (SLE) from three other main autoimmune diseases, rheumatoid arthritis, Sjögren’s disease and vasculitis with an average accuracy exceeding 90%. These results are extremely encouraging because the symptoms of SLE mimic other rheumatic, autoimmune diseases leading to more than 50% of the patients being initially misdiagnosed, mainly due to ambiguous laboratory test results. It is estimated that as many as 5 million people suffer from SLE and it may take up to 3 years from symptoms appearing to diagnosis and treatment.


Immunovia press release SLE

December 20th, 2016 08:12 R
Immunovia announces the start of PANFAM-1, the largest ever prospective multi-center clinical study for early detection of pancreatic cancer

Designed to validate IMMrayTM PanCan-d, the first blood-based test for early detection of pancreatic cancer.


Release

December 9th, 2016 11:12 R
Summary from the extraordinary general meeting of Immunovia

Extraordinary General Meeting of Immunovia AB (publ), 556730-4299, has been held in the confernce room ”Gamla Gästmatsalen”, House 302, Medicon Village, Scheelevägen 2, 223 63 Lund, December 9, 2016. Below is a summary of the resolutions of the extraordinary general meeting.


Release

December 9th, 2016 10:12 R
Immunovia announces collaboration with NCI, regarding early detection of pancreatic cancer in the new onset diabetes risk group

Immunovia and NCI (National Cancer Institute), has in a memorandum of understanding agreed to collaborate towards a common goal of cancer biomarker development and validation, in particular regarding early detection of pancreatic cancer in the risk group of new onset diabetes over 50 years.


Release

December 9th, 2016 08:12 R
Immunovia announces collaboration with the renowned Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid

LUND, Sweden, and MADRID, Spain ― Immunovia AB is delighted to announce the addition of the leading Spanish research centre Ramon y Cajal Institute for Health Research (IRYCIS) to a global network of leading sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer in high risk individuals. Designed to validate Immunovia ́s blood test, IMMrayTM PanCan-d, the study will run for three years across sites in both the US and Europe that offer high risk pancreatic cancer screening programs. 


Release

November 18th, 2016 16:11 R
Immunovia awarded 2016 Stars of Innovation Prize

Leading-edge healthcare diagnostics company making major progress in Europe.


Release

November 16th, 2016 08:11 R
KALLELSE TILL EXTRA BOLAGSSTÄMMA I IMMUNOVIA AB (publ)


Release

October 19th, 2016 17:10 R
Immunovia announces completion of preferential rights issue of SEK 28.7 million, adding to previously SEK 189.9 million directed issue

(LUND, Sweden) ― Immunovia AB, the Swedish molecular diagnostics company, announces today that it has successfully completed its SEK 28.7 million rights issue of which the subscription period ended on Monday October 17th. The underwriters, who had guaranteed 52% of the rights issue, will thereby not be assigned any shares through their guarantee.


Release

October 13th, 2016 13:10 R
Immunovia chosen as one of the three most innovative small to mid-companies in Europe 2016

Stars of Innovation nomination recognizes stellar performance since IPO


Release

October 7th, 2016 12:10 R
Immunovia: Insiders transfer subscription rights free of charge

LUND, Sweden ― Within the framework of the ongoing rights issue at Immunovia AB (publ) ("the company ") Carl Borrebaeck and Christer Wingren, Chairman of the Board and Chief Technical Officer respectively at the company, have, on request from professional investors and in consultation with the company's financial advisor Vator Securities, transferred all subscription rights received in the rights issue to named investors.


Press release PDF

September 26th, 2016 13:09 R
Immunovia publishes prospectus regarding preferential rights issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.

Immunovia publishes prospectus regarding preferential rights issue

Immunovia AB (publ) (”Immunovia” or the ”Company”) publishes prospectus in connection with the Company’s preferential rights issue (the “Rights Issue”).

Publication of prospectus
Immunovia’s prospectus, prepared in connection with the Rights Issue, has today been approved and registered by the Swedish Financial Supervisory Authority. The prospectus has today been published and is also available on the company’s web page http://immunovia.com/investors/ and the Company’s head office.


Press release PDF

September 15th, 2016 08:09 R
The board of directors of Immunovia resolves on a directed and preferential right issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.

The board of directors of Immunovia resolves on a directed and preferential right issue


Press release Immunovia resolves on a directed and preferential right issue

September 14th, 2016 17:09 R
Immunovia intends to launch a directed and preferential right issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.

Immunovia intends to launch a directed and preferential right issue

Summary
Immunovia AB (publ) (”Immunovia” or the ”Company”) intends to launch a directed share issue of approximately 2 300 000 of shares.

Thereafter, the Company, intends to launch a new share issue amounting to approximately SEK 30 million with preferential right for the Company’s existing shareholders.


Press release PDF

September 5th, 2016 08:09 R
Immunovia holdig detailed talks about participation in a large consortium that will address the largest risk group for pancreatic cancer

The best chance to influence the survival of non-hereditary pancreatic cancer patients is to focus on early detection of cases in people aged over 50 who receive their first diagnosis of diabetes. There is now clear unanimity on this, and both public authorities and health institutes focused on the link between diabetes and pancreatic cancer are initiating research programmes on a large scale across several countries in order to identify and assess the best ways to reduce fatality through early detection of pancreatic cancer among the diabetes risk group.


Press release PDF

August 24th, 2016 08:08 R
Immunovia Half-year report 2016


Press release PDF

August 17th, 2016 08:08 R
Immunovia invitation to a teleconference on 24 August 2016

Immunovia invites you to a teleconference in connection with the publishing of the first half-year report for 2016. The conference call will take place at 10 a.m. on 24 August and the results will be published at around 8.30 a.m. the same day


Press release PDF

August 16th, 2016 08:08 R
Immunovia announces intention to apply for listing on Nasdaq Stockholm's Main Market

The Board of Immunovia AB (publ) ("Immunovia" or the "Company") today announces its intention to apply during the first half of 2017 for a listing of its shares on Nasdaq Stockholm's Main Market. Immunovia’s shares are currently admitted for trading on the Nasdaq First North under the IMMNOV ticker.


Press release PDF

July 15th, 2016 10:07 R
Prof. Diane Simeone from University of Michigan Medical Center becomes latest appointment to Immunovia Scientific Advisory Board

Extensive expertise in clinical tumor management and tumor biomarkers, will help accelerate pancreatic cancer diagnostic program


Press release PDF

July 5th, 2016 08:07 R
World leading cancer diagnostics expert, Professor Aldo Scarpa appointed to Immunovia’s Scientific Advisory Board

LUND, Sweden ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Aldo Scarpa has been appointed to the company’s Scientific Advisory Board. Professor Scarpa is the Director of the ARC-Net Research Centre for Applied Research on Cancer and Chair of the Department of Pathology and Diagnostics at the University and Hospital Trust of Verona in Italy.


Press release PDF

June 23rd, 2016 14:06 R
Leading US gastrointestinal cancer expert, Professor Margaret Tempero appointed to Immunovia’s Scientific Advisory Board

LUND, Sweden ― As Immunovia maintains progress towards delivering the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Margaret Tempero has been appointed to the company’s Scientific Advisory Board. Currently, Professor Tempero is Director of the UCSF Pancreas Center and leader of the Pancreas Cancer Program at the UCSF.


Press release PDF

May 31st, 2016 09:05 R
Stämmokommuniké

Årsstämma i Immunovia AB (publ), 556730-4299 har hållits lokalen BioForum, hus 406, Medicon Village, Scheelevägen 2, 223 63 Lund den 30 maj 2016. Nedan följer en sammanfattning av de beslut som fattades.


Press release PDF

May 30th, 2016 10:05 R
Double pancreatic cancer survival by 2020

World Pancreatic Cancer Coalition (WPCC) and American Association for Cancer Research (AACR) Pancreatic Cancer Special Conference brought together patient advocacy groups and outstanding professionals 10-15 May, 2016 in Orlando, Florida to discuss pancreatic cancer, a disease with the lowest survival rates of any major cancer

Prof Borrebaeck presented in his AACR talk how serum biomarker signatures can detect early stages of pancreatic cancer


Press release PDF

May 30th, 2016 08:05 R
96 % of early stage pancreatic cancer patients detected in a clinical validation study with a North American sample cohort

Second study validates Immunovia´s IMMray™ PanCan-d test for early detection of pancreatic cancer  


Press release PDF

April 26th, 2016 10:04 R
Immunovia kallar till årsstämma 2016

Styrelsen i Immunovia AB (publ) har kallat  till årsstämma den 30 maj 2016. Stämman kommer att hållas kl 16.00 i samlingslokalen BioForum, hus 406, Medicon Village, Scheelevägen 2, 223 63 Lund.


PDF Press release

April 8th, 2016 11:04 R
Immunovia appoints Dr. Marco Del Chiaro from Karolinska Institute to Scientific Advisory Board

Dr. Del Chiaro brings deep experience in surgery of pancreatic diseases and identification of high risk individuals for pancreatic cancer.


Press release PDF

March 9th, 2016 12:03 R
Immunovia partners with leading healthcare consultingservices firm

Immunovia partners with leading healthcare consulting services firm to support market access of pancreatic cancer test in Germany
*
Immunovia announces agreement with Ehlers, Ehlers and Partner to develop and drive market access strategy of IMMray™ PanCan-d in Germany


PDF Press release

February 29th, 2016 15:02 R
Immunovia starts collaboration with multinational life science company on new systemic lupus erythematosus (SLE) diagnostics test

Immunovia and a large multinational life science company have agreed to run two studies aimed at evaluating Immunovia’s IMMray™ SLE-d for diagnosis of SLE


Press release PDF

February 24th, 2016 14:02 R
Immunovia Year-end report 2015


Year-end report 2015

February 10th, 2016 08:02 R
Immunovia and Lund University start clinical validation studies of Systemic Lupus Erythematosus (SLE) biomarker signatures

Immunovia initiates a new program to focus on the development, validation and commercialization of antibody array based tests for differential diagnostics and for prediction/monitoring of flares for SLE also known as “lupus”. 


Release

February 9th, 2016 09:02 R
Immunovia announces collaboration with Mount Sinai Health System to validate early detection blood test for pancreatic cancer

LUND, Sweden, and NEW YORK, USA ― Immunovia AB is pleased to announce that Mount Sinai Health System will be one of the first sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the US and Europe, starting second half of 2016.


Release

January 19th, 2016 10:01 R
Immunovia and the University of Liverpool enter into a collaboration in a prospective clinical study

LUND, Sweden, and Liverpool, UK ― Immunovia and the University of Liverpool enter into collaboration to validate early detection blood test for pancreatic cancer in a prospective clinical study. In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that the first European site participating in its prospective clinical study for the early diagnosis of pancreatic cancer will be the National Institute for Health Research (NIHR) Pancreatic Biomedical Research Unit, based at the Royal Liverpool University Hospital. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the US and Europe, starting in the second half of 2016.


Release

December 18th, 2015 13:12 R
White Paper outlines predicted impact of new biomarker diagnostic technology on pancreatic cancer survival rates

LUND, Sweden ― In this White Paper, Immunovia summarizes the clinical evidence retrospective studies performed so far on pancreatic cancer with IMMray™ PanCan-d. The blood based biomarker signature is able to detect pancreatic cancer in all stages, especially in resectable stage I and II, and thus has the potential to improve 5-year patient survival rates from 4-6% to 50-60%.


Release

December 3rd, 2015 11:12 R
IMMray™ PanCan-d detects 98% of pancreatic cancers in retrospective study with 1400 blood samples

Largest ever study for diagnosing pancreatic cancer paves way for early intervention to significantly improve survival rates.


Release

December 2nd, 2015 16:12 R
Immunovia’s stock increased 60 percent on first day of trading on Nasdaq First North with a turnover of SEK 28.5 million

Trading in Immunovia AB’s shares (IMMNOV) commenced yesterday on Nasdaq First North in Stockholm. At closing the share price had surged 60 percent compared to the introduction price. The interest among investors was high. The trading turnover was SEK 28.5 million during the day, thus setting a new record among comparable First North listings during 2015.